ArticleMedicine2026
Extracorporeal shockwave therapy for zoster-associated pain: A retrospective analysis based on spinal musculoskeletal imbalance.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes zoster-associated pain (ZAP) is a common sequela of varicella-zoster virus reactivation, particularly among older adults. Emerging evidence suggests that spinal musculoskeletal homeostasis (SMH) imbalance may contribute to localized degenerative changes associated with ZAP. Although extracorporeal shockwave therapy (ESWT) has shown promise in musculoskeletal rehabilitation, its efficacy in treating ZAP from the perspective of SMH remains underexplored. This retrospective study aims to evaluate the effectiveness of ESWT in ZAP patients with musculoskeletal imbalance as assessed by imaging-based SMH scores. This retrospective study reviewed clinical records of 82 hospitalized patients diagnosed with spinal-segmental ZAP between May 2023 and June 2024. Based on their treatment protocols, patients were divided into 2 groups: those receiving conventional treatment (C group, n = 41) and those receiving ESWT in addition to conventional therapy (E group, n = 41). Pain scores (Numerical Rating Scale, NRS), sleep quality (Pittsburgh Sleep Quality Index, PSQI), and Spinal Musculoskeletal Imaging Score (SMIS) were evaluated at 4 time points: 48 hours post-admission, after 1 week of hospitalization, and at 1 and 3 months post-discharge. Statistical analysis was performed using t tests and chi-square tests, with significance set at P < .05. Both groups had comparable baseline characteristics. After 1 week of treatment, both groups showed improvement in pain and sleep quality, but the ESWT group demonstrated a significantly greater improvement in PSQI (P < .05). At 1 month post-discharge, NRS, PSQI, and SMIS scores were significantly better in the ESWT group (P < .05). By 3 months, these differences further increased, with statistically significant reductions in all 3 indicators in the ESWT group (P < .01). The incidence of postherpetic neuralgia (PHN) was lower in the ESWT group (2 cases vs 13 cases in the control group). Retrospective analysis suggests that ESWT may be an effective adjunctive therapy for ZAP patients with spinal musculoskeletal imbalance, significantly improving pain, sleep quality, and spinal musculoskeletal structure, while potentially reducing the risk of PHN. These findings support the integration of ESWT into comprehensive ZAP management strategies based on musculoskeletal health assessments. Further prospective studies are needed to validate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.